Risk of drug-drug interactions in China's fight against COVID-19 and beyond

Qingpeng Zhang; Jiannan Yang; Daniel Dajun Zeng; Yibin Feng; Ian C.K. Wong

doi:10.1016/j.phrs.2023.106903

Risk of drug-drug interactions in China's fight against COVID-19 and beyond

Qingpeng Zhang^*, Jiannan Yang, Daniel Dajun Zeng, Yibin Feng, Ian C.K. Wong

^*Corresponding author for this work

Research output: Contribution to journal › Letter, comment/opinion or interview › peer-review

4 Downloads (Pure)

Abstract

Drug-drug interactions (DDIs) have significant impacts on patient health. In COVID-19, it is particularly important to be aware of DDIs due to the rapid development of new treatments and vaccines, as well as the widespread use of over-the-countered (OTC) drugs. Additionally, people who have COVID-19 may also be taking medications for comorbid conditions, increasing the potential for DDIs. Beyond the COVID-19 pandemic, the issue of drug interactions is further exacerbated by the aging population...

Original language	English
Article number	106903
Number of pages	2
Journal	Pharmacological Research
Volume	196
Early online date	9 Sept 2023
DOIs	https://doi.org/10.1016/j.phrs.2023.106903
Publication status	Published - Oct 2023

Bibliographical note

Funding

This work was supported by the Research Grants Council of the Hong Kong Special Administrative Region, China (Grant Nos. 11218221, C7154-20GF, C7151-20GF and C1143-20GF).

Keywords

COVID-19
Drug interactions
Network science
Protein-protein interactions

Access to Document

10.1016/j.phrs.2023.106903Licence: CC BY 4.0

Risk of drug-drug interactions in China's fight against COVID-19 and beyond
Copyright © 2023 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (https://creativecommons.org/licenses/by/4.0/).
Final published version, 952 KBLicence: CC BY 4.0

Cite this

@article{cc43bd116cb844b4bc811de9b4307fa7,

title = "Risk of drug-drug interactions in China's fight against COVID-19 and beyond",

abstract = "Drug-drug interactions (DDIs) have significant impacts on patient health. In COVID-19, it is particularly important to be aware of DDIs due to the rapid development of new treatments and vaccines, as well as the widespread use of over-the-countered (OTC) drugs. Additionally, people who have COVID-19 may also be taking medications for comorbid conditions, increasing the potential for DDIs. Beyond the COVID-19 pandemic, the issue of drug interactions is further exacerbated by the aging population...",

keywords = "COVID-19, Drug interactions, Network science, Protein-protein interactions",

author = "Qingpeng Zhang and Jiannan Yang and Zeng, {Daniel Dajun} and Yibin Feng and Wong, {Ian C.K.}",

note = "Copyright {\textcopyright} 2023 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (https://creativecommons.org/licenses/by/4.0/).",

year = "2023",

month = oct,

doi = "10.1016/j.phrs.2023.106903",

language = "English",

volume = "196",

journal = "Pharmacological Research",

issn = "1043-6618",

publisher = "Academic Press",

}

TY - JOUR

T1 - Risk of drug-drug interactions in China's fight against COVID-19 and beyond

AU - Zhang, Qingpeng

AU - Yang, Jiannan

AU - Zeng, Daniel Dajun

AU - Feng, Yibin

AU - Wong, Ian C.K.

PY - 2023/10

Y1 - 2023/10

N2 - Drug-drug interactions (DDIs) have significant impacts on patient health. In COVID-19, it is particularly important to be aware of DDIs due to the rapid development of new treatments and vaccines, as well as the widespread use of over-the-countered (OTC) drugs. Additionally, people who have COVID-19 may also be taking medications for comorbid conditions, increasing the potential for DDIs. Beyond the COVID-19 pandemic, the issue of drug interactions is further exacerbated by the aging population...

AB - Drug-drug interactions (DDIs) have significant impacts on patient health. In COVID-19, it is particularly important to be aware of DDIs due to the rapid development of new treatments and vaccines, as well as the widespread use of over-the-countered (OTC) drugs. Additionally, people who have COVID-19 may also be taking medications for comorbid conditions, increasing the potential for DDIs. Beyond the COVID-19 pandemic, the issue of drug interactions is further exacerbated by the aging population...

KW - COVID-19

KW - Drug interactions

KW - Network science

KW - Protein-protein interactions

UR - http://www.scopus.com/inward/record.url?scp=85170520360&partnerID=8YFLogxK

UR - https://www.sciencedirect.com/science/article/pii/S1043661823002591?via%3Dihub

U2 - 10.1016/j.phrs.2023.106903

DO - 10.1016/j.phrs.2023.106903

M3 - Letter, comment/opinion or interview

C2 - 37690534

AN - SCOPUS:85170520360

SN - 1043-6618

VL - 196

JO - Pharmacological Research

JF - Pharmacological Research

M1 - 106903

ER -

Risk of drug-drug interactions in China's fight against COVID-19 and beyond

Abstract

Bibliographical note

Funding

Keywords

Access to Document

Other files and links

Fingerprint

Cite this